This was revealed by absence of therapeutic response to DAC treatment in ST2−/− tumor-bearing mice and by 3D microfluidic chip experiments showing lack of migration of ST2−/− immune cells towards DAC/IL-33 treated tumors. Here, IL33 is linked to neoplasm.